CalciMedica, Inc. Files 8-K Report
Ticker: CALC · Form: 8-K · Filed: Mar 29, 2024 · CIK: 1534133
| Field | Detail |
|---|---|
| Company | Calcimedica, INC. (CALC) |
| Form Type | 8-K |
| Filed Date | Mar 29, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $4,700,000, $17,068,386, $279,771.74 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, financial-statements, exhibits
Related Tickers: CALC
TL;DR
CALCI files 8-K with financial statements & exhibits. Standard disclosure.
AI Summary
On March 29, 2024, CalciMedica, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating routine corporate disclosures rather than a specific material event. The company, formerly known as Graybug Vision, Inc., is incorporated in Delaware and headquartered in La Jolla, California.
Why It Matters
This filing serves as a standard disclosure for CalciMedica, Inc., providing updates on financial statements and exhibits to the SEC. Investors should review the full filing for detailed financial information.
Risk Assessment
Risk Level: low — This filing is a routine 8-K report for financial statements and exhibits, not indicating any significant new risks or events.
Key Players & Entities
- CalciMedica, Inc. (company) — Registrant
- Graybug Vision, Inc. (company) — Former company name
- La Jolla, California (location) — Principal Executive Offices
- March 29, 2024 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing for CalciMedica, Inc.?
The primary purpose of this 8-K filing is to report on 'Other Events' and 'Financial Statements and Exhibits' as of March 29, 2024.
What was CalciMedica, Inc. formerly known as?
CalciMedica, Inc. was formerly known as Graybug Vision, Inc., with previous name changes also noted.
Where are CalciMedica, Inc.'s principal executive offices located?
CalciMedica, Inc.'s principal executive offices are located at 505 Coast Boulevard South, Suite 307, La Jolla, California, 92037.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported in this filing is March 29, 2024.
Under which section of the Securities Exchange Act is this Current Report filed?
This Current Report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 529 words · 2 min read · ~2 pages · Grade level 9.7 · Accepted 2024-03-29 08:35:33
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share CALC The Nasdaq Capital M
- $4,700,000 — ight & Co., dated August 11, 2023, from $4,700,000 to $17,068,386 and filed a prospectus s
- $17,068,386 — ted August 11, 2023, from $4,700,000 to $17,068,386 and filed a prospectus supplement (the
- $279,771.74 — tock having an aggregate sales price of $279,771.74 under the Offering Agreement. A copy of
Filing Documents
- d818025d8k.htm (8-K) — 25KB
- d818025dex51.htm (EX-5.1) — 10KB
- g818025dsp01.jpg (GRAPHIC) — 4KB
- 0001193125-24-081584.txt ( ) — 168KB
- calc-20240329.xsd (EX-101.SCH) — 3KB
- calc-20240329_lab.xml (EX-101.LAB) — 18KB
- calc-20240329_pre.xml (EX-101.PRE) — 11KB
- d818025d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 5.1 Opinion of Cooley LLP 23.1 Consent of Cooley LLP (included in Exhibit 5.1) 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CalciMedica, Inc. Date: March 29, 2024 By: /s/ A. Rachel Leheny, Ph. D. Name: A. Rachel Leheny, Ph. D. Title: Chief Executive Officer